-
Phigenix, Inc. v. Genentech, Inc. DC CAFC
- 5:15-cv-01238
- N.D. Cal.
- Judge: Beth Labson Freeman
+1
- Filed: 03/17/2015
- Closed: 08/23/2017
- Latest Docket Entry: 10/15/2019
- PACER
- Docket updated daily
1
Plaintiff
1
Defendant
1
Accused
Product
1
Patent-in-Suit
1,301
Days in
Litigation
-
Phigenix, Inc. v. Genentech, Inc. DC CAFC
- 5:15-cv-01238
- N.D. Cal.
- Judge: Beth Labson Freeman
+1
- Filed: 03/17/2015
- Closed: 08/23/2017
- Latest Docket Entry: 10/15/2019
- PACER
- Docket updated daily
Market Sector
Biotech and Pharma
Referred Judge
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
| Claim # | Claim Text | Outcome |
|---|---|---|
| 1 |
A method for treating a breast condition in a subject, comprising administering to a breast tissue of the subject, a composition that (1) inhibits PAX2 expression or PAX2 activity, (2) expresses DEFB1 or (3) inhibits PAX2 expression or PAX2 activity
view more
|
Invalid (112)
Entry 327 |
| 2 |
The method of claim 1, wherein the breast condition is breast cancer or mammary intraepithelial neoplasia (MIN).
|
Invalid (112)
Entry 327 |
| 8 |
A method of treating breast cancer or MIN in a subject, comprising enhancing expression of DEFB1 in a breast cancer tissue or MIN tissue in the subject.
|
Invalid (112)
Entry 327 |
-
Infringement
Genentech, Inc.
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| KADCYLA | US 8,080,534 B2 | All Asserted Claims |
No infringement
Entry 392
|
-
Damages
